Administration of a thiol-based chemoprotectant compound

Abstract

A method of administration of a thiol-based chemoprotectant agent including NAC (N-acetylcysteine) and STS (sodium thiosulfate) that markedly affects biodistribution and protects against injury from diagnostic or therapeutic intra-arterial procedures. A method for treating or mitigating the side effects of cytotoxic cancer therapy for tumors located in the head or neck and brain tumors. The thiol-based chemoprotectant agent is administered intra-arterially with rapid and first pass uptake in organs and tissues other than the liver.

1 . A method for treating or mitigating the side effects of cytotoxic cancer therapy comprising administering sodium thiosulfate (STS) in conjunction with a cis-platinum compound, wherein the STS is administered about 4 hours after administration of the cis-platinum compound, and wherein the STS is at a dose from 5 g/m 2  to 40 g/m 2 . 
     
     
         2 . The method for treating or mitigating the side effects of cytotoxic cancer therapy of  claim 1  wherein the STS is administered intravenously. 
     
     
         3 . The method for treating or mitigating the side effects of cytotoxic cancer therapy of  claim 1  wherein the STS is administered intra-arterially. 
     
     
         4 . The method for treating or mitigating the side effects of cytotoxic cancer therapy of  claim 3  wherein the cancer is a cancer located in the brain, head or neck. 
     
     
         5 . A method for treating or mitigating the side effects of cytotoxic cancer therapy comprising administering sodium thiosulfate (STS) in conjunction with a cis-platinum compound, wherein the STS is administered from about 4 hours to 8 hours after administration of the cis-platinum compound, and wherein the STS is at a dose from 5 g/m 2  to 40 g/m 2 . 
     
     
         6 . A method for treating or mitigating the side effects of cytotoxic cancer therapy comprising administering sodium thiosulfate (STS) in conjunction with a cis-platinum compound, wherein the STS is administered about 4 hours after administration of the cis-platinum compound, and wherein the STS is administered intravenously at a dose from 5 g/m 2  to 40 g/m 2 . 
     
     
         7 . The method of  claim 1  wherein administration of the cis-platinum compound is directed to a region where the tumor is located and administration of the STS is directed to normal tissues. 
     
     
         8 . The method of  claim 5  wherein administration of the cis-platinum compound is directed to a region where the tumor is located and administration of the STS is directed to normal tissues. 
     
     
         9 . The method of  claim 6  wherein administration of the cis-platinum compound is directed to a region where the tumor is located.